MVA-SARS-2-S
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- MVA-SARS-2-S
- Accession Number
- DB16432
- Description
MVA-SARS-2-S is a COVID-19 vaccine candidate that contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein2. MVA is a highly attenuated poxvirus vector1 that has a high-level of biological safety due to its quality of being a non-replicating virus in mammalian hosts3 and is used to develop vaccines for infectious diseases and cancer1.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Not Available
- External IDs
- MVA-SARS-2-S
Pharmacology
- Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset
- Indication
- Not Available
- Contraindications & Blackbox Warnings
- Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
- Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Chiuppesi F, Salazar MD, Contreras H, Nguyen VH, Martinez J, Park Y, Nguyen J, Kha M, Iniguez A, Zhou Q, Kaltcheva T, Levytskyy R, Ebelt ND, Kang TH, Wu X, Rogers TF, Manuel ER, Shostak Y, Diamond DJ, Wussow F: Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. Nat Commun. 2020 Nov 30;11(1):6121. doi: 10.1038/s41467-020-19819-1. [PubMed:33257686]
- ClinicalTrials.gov: Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19 [Link]
- DZIF: MVA-SARS-2-S DZIF COVID-19 vaccine candidate [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on January 14, 2021 17:41 / Updated on January 16, 2021 21:46